
|Articles|April 30, 2007
FDA denies Lilly appeal
The FDA has denied Eli Lilly's appeal of the agency's ruling requiring it to conduct an additional three-year study of ruboxistaurin mesylate (Arxxant) before it can be approved for treating diabetic retinopathy (DR).
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times Europe
1
Review highlights gaps in transition from paediatric to adult eye care
2
Beyond anti-VEGF: The next wave in retinal therapy
3
The real cost of persistent epithelial defects: Lessons from an NHS audit
4
Trehalose-hyaluronate combination aids tear film after eyelid surgery
5




















